ReviewRomanian journal of ophthalmology
Updates on Corneal Collagen Cross-Linking for Keratoconus: A 10-Year Review of Techniques, Clinical Outcomes, and Future Directions.
Review in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To synthesize major advances in corneal collagen cross-linking (CXL) for keratoconus over the past decade (2015-2025), with emphasis on protocol evolution, comparative effectiveness (epithelium-off vs. epithelium-on; conventional vs. accelerated), pediatric outcomes, repeat and customized approaches, adjunctive therapies, biomechanical assessment, safety, and emerging strategies, including oxygen supplementation and topography-guided CXL. Design: Structured narrative review. Materials and methods: A systematic literature survey of randomized controlled trials, prospective cohort studies, registry analyses (including the Save Sight Keratoconus Registry), meta-analyses, and long-term follow-up studies published between 2015 and early 2025 was conducted. Extracted outcomes included maximum keratometry (Kmax), mean keratometry (Kmean), corrected distance visual acuity (CDVA), corneal thickness, progression and re-treatment rates, and complication profiles across protocols (standard epithelium-off, accelerated, transepithelial/epithelium-on, repeat CXL, and combination procedures). Results: Long-term evidence supports standard epithelium-off (Dresden) CXL as the reference protocol for biomechanical stabilization, with durable arrest of progression in most treated eyes and sustained improvements in corneal shape and CDVA through 5-10 years in several large cohorts. Accelerated protocols provide comparable short-term stabilization and reduce operative time, but may show shallower demarcation lines and less consistent long-term flattening in some series, particularly when pulsed delivery or oxygen enhancement is not used. Transepithelial (epithelium-on) techniques reduce postoperative pain and epithelial complications but, in meta-analyses, generally yield less keratometric flattening than epithelium-off CXL; newer riboflavin formulations, iontophoresis, oxygen supplementation, and pulsed UVA delivery have narrowed this efficacy gap. Pediatric keratoconus benefits from early CXL but has higher rates of late progression and retreatment than adult cohorts. Combined strategies (intracorneal ring segments and/or topography-guided surface ablation with CXL) can improve optical quality in selected eyes with adequate stromal reserve. PACK-CXL remains investigational as an adjunctive therapy for infectious keratitis. Overall complication rates are low; transient haze is the most common complication, and serious adverse events are rare when pachymetric safety thresholds are respected. Discussions: Over the past decade, CXL has evolved from a single Dresden protocol to a spectrum of approaches that balance efficacy, safety, comfort, and practicality. Long-term cohort evidence continues to support epithelium-off Dresden CXL as the reference standard for robust biomechanical stabilization. Conclusions: CXL has evolved from a single protocol into a versatile therapeutic platform. The Dresden epithelium-off technique remains the efficacy benchmark for robust biomechanical reinforcement, while optimized accelerated and epithelium-on approaches expand treatment options. Key future directions include oxygen-enhanced photochemistry, personalized/topography-guided CXL, and integration of biomechanical imaging into patient-specific planning and long-term monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.